Remove 2013 Remove Patients Remove Pharmaceutical products
article thumbnail

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

European Pharmaceutical Review

For at least a decade from 2013 until recently, LDL lowering treatments were stuck on a paradigm of just putting people on statins and not getting LDL levels down to certain goals” CETP inhibitors have been around for a while, but they have unfortunately been unsuccessful in getting onto the market commercially. “For

Pharma 97
article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 23 April 2013.

article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient. About 800 million humans are injected with vaccines every year” Most vaccines in use today are relatively cheap to make and are injected into patients with mass‑produced and inexpensive (five-cent) disposable syringes.